Semaglutide

Common side effects:

• Nausea and vomiting, particularly during the initial dose escalation phase.
• Diarrhea or constipation due to altered gastrointestinal motility.
• Abdominal pain and general gastrointestinal discomfort.
• Fatigue and occasional dizziness.
• Decreased appetite leading to potential unintended lean mass loss Bikou A et al., 2024.

Rare or serious side effects:

• Pancreatitis, requiring immediate discontinuation of the medication.
• Gallbladder disease, including cholelithiasis and cholecystitis.
• Risk of nonarteritic anterior ischemic optic neuropathy Hathaway JT et al., 2024.
• Potential risk of thyroid C-cell tumors based on rodent studies.

Receptor activation drives the primary mechanism of the Semaglutide peptide, as it selectively binds to and activates the GLP-1 receptor. This incretin mimetic action stimulates glucose-dependent insulin secretion from pancreatic beta cells while simultaneously suppressing inappropriate glucagon secretion from alpha cells. Consequently, blood glucose levels stabilize without a high risk of hypoglycemia.

Central nervous system engagement is responsible for the profound Semaglutide benefits related to weight loss. The peptide crosses the blood-brain barrier to interact with the hypothalamus and hindbrain, directly modulating appetite and satiety signals Gabery S et al., 2020. Additionally, it slows gastric emptying, which prolongs the feeling of fullness and reduces overall caloric intake.

Discovery and development of Semaglutide was spearheaded by Novo Nordisk researchers aiming to create a longer-acting alternative to liraglutide Knudsen LB et al., 2019. By modifying the human GLP-1 molecule, scientists substituted an amino acid to resist DPP-4 degradation and attached a fatty acid diacid to promote albumin binding. This structural innovation extended the half-life to approximately one week, allowing for convenient once-weekly subcutaneous dosing Yang XD et al., 2024.

Regulatory milestones began with FDA approval of Ozempic in 2017 for type 2 diabetes management. Subsequent clinical trials, such as the STEP program, demonstrated massive weight loss efficacy, leading to the 2021 approval of Wegovy specifically for chronic weight management Davies M et al., 2021. Today, it remains a heavily researched compound, with ongoing trials investigating its effects on heart failure and adiposopathy NCT05371496.